NNBP Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
NNBP FAQ
What was Nanobac Pharmaceuticals Incorporated’s price range in the past 12 months?
Currently, no data Available
What is Nanobac Pharmaceuticals Incorporated’s market cap?
Nanobac Pharmaceuticals Incorporated’s market cap is $24.95K.
When is Nanobac Pharmaceuticals Incorporated’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Nanobac Pharmaceuticals Incorporated’s earnings last quarter?
Currently, no data Available
Is Nanobac Pharmaceuticals Incorporated overvalued?
According to Wall Street analysts Nanobac Pharmaceuticals Incorporated’s price is currently Overvalued.
Does Nanobac Pharmaceuticals Incorporated pay dividends?
Nanobac Pharmaceuticals Incorporated does not currently pay dividends.
What is Nanobac Pharmaceuticals Incorporated’s EPS estimate?
Nanobac Pharmaceuticals Incorporated’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nanobac Pharmaceuticals Incorporated have?
Nanobac Pharmaceuticals Incorporated has 249,507,000 shares outstanding.
What happened to Nanobac Pharmaceuticals Incorporated’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Nanobac Pharmaceuticals Incorporated?
Currently, no hedge funds are holding shares in NNBP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Nanobac Pharmaceuticals Incorporated
Nanobac Pharmaceuticals, Incorporated is dedicated to advancing human health through the creation and refinement of products and services designed for the identification and management of calcifying nanoparticles (CNPs). The company's offerings include the production and sale of in vitro diagnostic (IVD) kits, which encompass assays, antibodies, and reagents specifically developed for detecting CNPs. Notably, their diagnostic assays include NANO-CAPTURE and NANO-SERO. Furthermore, Nanobac engages in research and clinical studies focused on various urological diseases—such as chronic prostatitis/chronic pelvic pain syndrome, kidney stones, and polycystic kidney diseases—as well as cardiovascular ailments. Established in 1994 and headquartered in Tampa, Florida, the company operated as HealthCentrics Inc. until its name change to Nanobac Pharmaceuticals, Incorporated in December 2002.
Scinai Immunotherapeutics
―
Oragenics
―
PainReform
―
Universe Pharmaceuticals
―
Pasithea Therapeutics Corp
―
Ownership Overview
―
Insiders
―
Mutual Funds
0.02% Other Institutional Investors
99.98% Public Companies and
Individual Investors